A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Advanced Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase III, Multicentered, Randomized, Double-blinded, Parallel Controlled Study to Evaluate Camrelizumab (PD-1 Antibody) in Combination With FOLFOX4 Regimen Versus Placebo in Combination With FOLFOX4 Regime in First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC).

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03605706
• Other study ID #: SHR-1210-III-305-HCC
• Status: Recruiting
• Phase: Phase 3
• Start date: May 31, 2019
• Est. completion date: December 2023

Study information

• Verified date: February 2022
• Source: Jiangsu HengRui Medicine Co., Ltd.
• Contact: Linna Wang, MD
• Phone: 021-60453196
• Email: wanglinna[@]hrglobe.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is being conducted to evaluate the efficacy and safety of SHR-1210 plus FOLFOX4 in subjects with advanced HCC who have never received prior systemic treatment compared to placebo plus FOLFOX4. The primary study hyposis is that Camrelizumab combined with FOLFOX4 treatment can improve Overall Survival when compared with placebo in combination with FOLFOX4 Regimen.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 396
• Est. completion date: December 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Has not received prior systemic treatment for their advanced/metastatic HCC. Has measurable disease according to RECIST v1.1. ECOG Performance Status of 0 or 1. Child-Pugh Class A or B with 7 points. Life Expectancy of at least 12 weeks. HBV DNA<500 IU/ml. Adequate organ function: Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug. Exclusion Criteria: Known fibrolamellar HCC, Prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured. Known or occurrence of central nervous system (CNS) metastases. Ascites with clinical symptoms. Known or evidence of GI hemorrhage within the past 6 months. Known or occurrence of hemorrhage/ thrombus. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias. Grade III~IV cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF<50%. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 150mmHg, diastolic blood pressure > 90 mmHg). History of hepatic encephalopathy. Known history of human immunodeficiency virus (HIV) infection. Active infection or an unexplained fever > 38.5°C during screening visits. Prior or planning to organ transplantation including liver transplantation. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity. Proteinuria= 2+ and 24 hours total urine protein > 1.0 g. Active known, or suspected autoimmune disease. Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Any loco-regional therapy to liver (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks prior to study. Known history of hypersensitivity to monoclonal antibodies or any components of the study drugs. Pregnant or breast-feeding women. According to the investigator, other conditions that may lead to stop the research.

Related Conditions & MeSH terms

• Advanced Hepatocellular Carcinoma
• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• SHR-1210
Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
• FOLFOX4
Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
• Placebo
Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

Locations

Country	Name	City	State
China	81 Hospital Nanjing	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	OS was defined as the time from randomization to death due to any cause	Up to approximately 3 years
Secondary	Objective Response Rate (ORR) per RECIST 1.1 in all participants	ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: =30% decrease in the sum of diameters of target lesions) per RECIST 1.1.	Up to approximately 6 months
Secondary	Time to Progression (TTP) per RECIST 1.1 in all participants		Up to approximately 3 years
Secondary	Duration of Response (DoR) per RECIST 1.1 in all participants		Up to approximately 3 years
Secondary	Disease Control Rate (DCR) per RECIST 1.1 in all participants		Up to approximately 3 years
Secondary	Progression-free Survival (PFS) per RECIST 1.1 in all participants		Up to approximately 3 years
Secondary	AE		Up to approximately 3 years
Secondary	Overall Survival (OS) rate at 9 months and 12 months		Up to approximately 9 months and 12 months